Intellia Therapeutics, Inc.
NTLA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$12.74
▲ +0.47%
P/E
-3.79
Mkt Cap
$1.8B
52-Wk Range
$7.95–$28.25
52-Week Range
$7.95 - $28.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CRISPR/Cas9 technology
- Diverse therapeutic pipeline
- Strategic pharmaceutical partnerships
- Advanced genetic engineering capabilities
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Revenue decline expected
Expanding genetic medicine market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-5.6% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NTLA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.80 vs -$0.80 consensus (-0.1% surprise). Revenue of $7.7M vs $13.0M expected (-41.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-0.1%
Revenue trend · last 8Q
—
+772%
-43%
+105%
+51%
+79%
-9%
-46%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.1M
$12.9M
$16.6M
$14.2M
$13.8M
$23.0M
$15.0M
$7.7M
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
-1392.3%
Wall Street consensus
12 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
33%
Sell
17%
Median Price Target
—
Latest: Citi · Aug 25, 2026
vs Industry
How NTLA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related